SK Life Science to Present Epilepsy Research at AAN 2026

New data on cenobamate and insights from 'Hope, Hesitancy, and Hard Truths' survey to be shared at annual neurology conference.

Apr. 6, 2026 at 12:19pm

Got story updates? Submit your updates here. ›

SK Life Science, Inc. will present multiple posters at the 2026 American Academy of Neurology (AAN) Annual Meeting, highlighting clinical and real-world evidence related to its antiseizure medication cenobamate, as well as new insights into the experiences and perspectives of people living with epilepsy and their healthcare providers.

Why it matters

Understanding communication between epilepsy patients and providers is crucial to improving care, as nearly 40% of people with epilepsy do not achieve seizure freedom despite available treatments. The 'Hope, Hesitancy, and Hard Truths' survey aims to identify barriers in treatment discussions that may influence care decisions.

The details

The AAN 2026 presentations will include analyses of cenobamate's impact on healthcare utilization, seizure outcomes, safety and efficacy, pharmacokinetics, treatment pathways, and long-term data. A new methodological analysis from the 'Hope, Hesitancy, and Hard Truths' survey will also be shared, providing additional detail on the survey design and respondent perspectives.

  • The AAN 2026 Annual Meeting will take place April 18–22, 2026, in Chicago, Illinois.
  • Initial findings from the 'Hope, Hesitancy, and Hard Truths' survey were shared during National Epilepsy Awareness Month in November 2025.

The players

SK Life Science, Inc.

A U.S. subsidiary of SK Biopharmaceuticals Co., Ltd. that is advancing treatments for central nervous system disorders and oncology.

Sunita Misra, MD, PhD

Chief Medical Officer of SK Life Science, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“Understanding how patients and healthcare providers communicate about epilepsy is essential to improving care.”

— Sunita Misra, MD, PhD, Chief Medical Officer, SK Life Science, Inc.

What’s next

Full presentation details, including session times and locations, are available in the official AAN Annual Meeting program.

The takeaway

The research presented at AAN 2026 aims to provide valuable insights into the experiences and perspectives of both people living with epilepsy and their healthcare providers, with the goal of identifying communication gaps that may influence treatment decisions and patient outcomes.